Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade Structure of Toripalimab Biosimilar

Toripalimab Biosimilar is a monoclonal antibody that specifically targets the programmed cell death protein 1 (PD-1) receptor. It is a biosimilar version of Toripalimab, an FDA-approved immunotherapy for the treatment of various types of cancer. The structure of Toripalimab Biosimilar is similar to that of Toripalimab, with a molecular weight of approximately 150 kDa and a structure consisting of two heavy chains and two light chains.

Activity of Toripalimab Biosimilar

Toripalimab Biosimilar works by binding to the PD-1 receptor on the surface of T cells, which are important immune cells in the body. The PD-1 receptor plays a crucial role in regulating the immune response by inhibiting T cell activity. By binding to the PD-1 receptor, Toripalimab Biosimilar blocks its inhibitory function and allows the T cells to become activated, leading to a stronger immune response against cancer cells.

Toripalimab Biosimilar has been shown to have a high affinity and specificity for the PD-1 receptor, making it a potent immunotherapy for cancer treatment. It has also been shown to have a longer half-life compared to other anti-PD-1 antibodies, allowing for less frequent dosing and potentially reducing treatment costs.

Application of Toripalimab Biosimilar

Toripalimab Biosimilar is primarily used as a therapeutic agent for the treatment of various types of cancer, including melanoma, lung cancer, and bladder cancer. It has also shown promising results in clinical trials for other types of cancer, such as gastric cancer and hepatocellular carcinoma.

As a biosimilar version of Toripalimab, this antibody offers a more affordable option for cancer treatment while maintaining the same efficacy and safety profile. It is also a valuable tool for researchers studying the PD-1 pathway and developing new immunotherapies for cancer treatment.

Conclusion

Toripalimab Biosimilar is a potent anti-PD-1 monoclonal antibody with a similar structure and activity to the FDA-approved Toripalimab. It works by blocking the inhibitory function of the PD-1 receptor, leading to a stronger immune response against cancer cells. This biosimilar version offers a more affordable option for cancer treatment and is also a valuable tool for research in the field of cancer immunotherapy.

Keywords

Antibody, therapeutic target, Toripalimab Biosimilar, anti-PDCD1, PD1, CD279 mAb, research grade, structure, activity, application.

Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1540) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450